Evaluation of the pharmacoeconomic reasonableness of using fixed combinations of ingks and intranasal antihistamine drugs

Allergic rhinitis (AR) remains a significant medical and social problem that requires effective and cost-effective approaches to therapy. The article discusses the pharmacoeconomic rationale for using fixed combinations (FC): mometasone furoate+azelastine, mometasone furoate+olopatadine, in comparison with the combination of fluticasone propionate+azelastine. The article analyzes the clinical efficacy, safety profile, and impact on patients’ quality of life in the context of direct